Challenges in the treatment of gastrointestinal tumours

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Labianca, R ^a   Berardi, E ^b   Malugani, F ^b  

^a OSPEDALI RIUNITI   (Italy)

^b Ospedale Civile   (Italy)

Author keywords

Colorectal; Gastric and pancreatic cancer; Gastrointestinal tumours; Monoclonal antibodies; Prognostic factors; Target therapies

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PACLITAXEL; TANOMASTAT; TEGAFUR;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COLON SURGERY; COLORECTAL CANCER; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; EARLY DIAGNOSIS; GASTRECTOMY; GASTROINTESTINAL TUMOR; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 33745728904     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj969     Document Type: Review

References (80)

1. Esser S, Reilly WT, Riley LB et al. The role of sentinel lymph node mapping in staging of colon and rectal cancer. Dis Colon Rectum 2001; 44 (6): 850-4; discussion 854-6.
2. Bilchik AJ, Nora DT, Sobin LH et al. Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol 2003; 21 (4): 668-72.
3. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322 (6): 352-8.
4. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345 (8955): 939-44.
5. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17 (11): 3553-9.
6. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264 (11): 1444-60.
7. De Gramont A, Banzi M, Navarro M et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proceedings of the American Society of Clinical Oncology 2003; 22: A-1015.
8. Twelves C, Wong A, Nowacki MP et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. N Engl J Med 2005; 352: 2696-2704.
9. Petrasch S, Schmiegel W. Adjuvant therapy of colon carcinoma: Results of two Intergroup Studies (INT-0035 and INT-0089), a study by the German Cancer Aid 17-1A Study Group and the IMPACT Study. Gastroenterol 1997; 35(1): 49-52.
10. Gray RG, Barnwell J, Hills R et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients. Proceedings of the American Society of Clinical Oncology 2004; 22 (14S): Abstract No: 3501.
11. O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16 (1): 295-300.
12. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17 (5): 1349-55.
13. Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13 (12): 2936-43.
14. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17 (5): 1356-63.
15. Joseph NE, Sigurdson ER, Hanlon AL et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003; 10(3): 213-8.
16. Wong JH, Bowles BJ, Bueno R, Shimizu D. Impact of the number of negative nodes on disease-free survival in colorectal cancer patients. Dis Colon Rectum 2002; 45(10): 1341-8.
17. Maurer CA, Renzulli P, Kasparek MS et al. The role of lymph nodes in colon carcinoma. Zentralbl Chir 2000; 125 (10): 863-9.
18. Wong JH et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17(9): 2896-900.
19. Van Cutsem E, Labianca R, Hossfeld D et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) Proceedings of the American Society of Clinical Oncology 2005; Abstract No: 8.
20. Niv Y. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Mad Assoc J 2005; 7(8): 520-4.
21. Guerrero D, Balen E, Martinez-Penuela JM et al. Association between microsatellite instability and clinico-pathological characteristics in sporadic colon cancer. Med Clin (Barc) 2005; 124(12): 441-6.
22. Kohonen-Corish MR, Daniel JJ Chan C et al. Low microsatellite instability is associated with poor prognosis in stage C colon cancer. J Clin Oncol 2005; 23(10): 2318-24.
23. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13): 905-14.
24. De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16): 2938-47.
25. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22 (2): 229-37.
26. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22 (1): 23-30.
27. Conti JA, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14 (3): 709-15.
28. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13): 905-14.
29. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355 (9209): 1041-7.
30. De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic oolorectal cancer. Eur J Cancer 1997; 33 (2): 214-9.
31. Cunningham D, Humblet Y, Siena S et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, innotecan-refractory metastatic colorectal cancer (MCRC). [Abstract] Proceedings of the American Society of Clinical Onoology 2003; 22: A-1012.
32. Hurwitz H, Fehrenbacher L, Cartwright T et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proceedings of the American Society of Clinical Oncology 2003; 22: A-3646.
33. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1991; 62: 440-443.
34. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002; 95: 2096-2102.
35. Bozzetti F, Marubini E, Bonfanti G et al. Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized Italia trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170-178.
36. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077.
37. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
38. Degiuli M, Sasako M, Ponti A et al. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004; 90: 1727-1732.
39. Mari E, Floriani A, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer. A meta-analysis of published randomized trials. Ann Oncol 2000; 11: 837-840.
40. Wagner AD et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005; 18; (2): CD004064.
41. Gotze T, Schutte K, Rocken C et al. Recent developments in chemotherapy of advanced gastric cancer. Dig Dis 2004; 22(4): 360-5.
42. Graziano F, Cardarelli N, Marcellini M et al. A pilot clinical trial of postoperative intensive weekly chemotherapy using cisplatin, epi-doxorubicin, 5-fluorouracil, 6S-leucovorin, glutathione and filgrastim in patients with resected gastric cancer. Tumori 1998; 84: 368-371.
43. Cascinu S, Labianca R, Graziano F et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1998; 78: 390-393.
44. Cascinu S, Labianca R, Barone C et al. Italian Group for the Study of Digestive Tract Cancer (GISCAD). High risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen. Proceedings of the American Society of Clinical Oncology 2005; A-4023.
45. Macdonald JS, Role of post-operative chemoradiation in resected gastric cancer. J Surg Oncol 2005; 90 (3): 166-70.
46. Lowy AM, Feig BW, Janjan N et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer: A phase I-II study; Ann Oncol 2001; 8 (6): 519-24.
47. Roth AD, Allal AS, Brundler MA et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: A phase I-II study; Ann Oncol 2003; 14 (1): 110-5.
48. Scartozzi M, Labianca R. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Proceedings of the American Society of Clinical Oncology 2005; A-77.
49. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18 (14): 2648-57.
50. Wilke H, Wils J, Rougier P et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/5-FU in advanced gastric cancer. Proceedings of the American Society of Clinical Oncology 1995; 14: A-206.
51. Diaz-Rubio E. New chemotherapeutic advanced in pancreatic, colorectal and gastric cancer. The Oncologist 2004; 9: 282-294.
52. Phan AT, Ajani JA. Gastric Carcinoma. Current Oncology Reports 2004; 6; 192-198.
53. Ajani JA, Fairweather J, Dumas P et al. Phase II study of Taxol in patients with gastric carcinoma. Cancer J Sci Am 1998; 4: 269-274.
54. Sulkes A, Smyth J, Sessa C et al. Docetaxel in advanced gastric cancer: Results of a phase II clinical trial: EORTC Early Clinical Trials Group. Br J Cancer 1994; 70: 380-383.
55. Takiuchi T, Ajani JA. Uracil-tegafur in gastric carcinoma: A comprehensive review. J Clin Oncol 1998; 16: 2877-2885.
56. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295-301.
57. Roth AD, Maibach R, Martinelli G et al. Docetaxell (Taxotere)- cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000; 11: 301-306.
58. Al-Batran S-E, Atmaca A, Hegewisch-Becker S et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663.
59. Moehler M, Haas U, Siebler J et al. Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer. Anticancer Drugs 2003; 14: 645-650.
60. Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. Proceedings of the American Society of Clinical Oncology 2005; A-4014.
61. Al-Batran S. Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy for patients with advanced gastric cancer; first interim analysis of a randomised multicenter phase II study. Proceedings of the American Society of Clinical Oncology 2005; A-4015.
62. Duyster J. Oxaliplatin plus 5FU/Folinic acid (FUFOX Regimen) in 1st Line Metastatic Gastric Cancer (MGC). Results of the Multicenter Phase II STOMOX Trial. Proceedings of the American Society of Clinical Oncology 2005; A-4016.
63. Neoptolemos JP, Stocken DD, Friess H et al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. N Engl J Med 2004; 350: 1200-10.
64. ESPAC-3(v2) Phase III Adjuvant Trial in Pancreatic Cancer Comparing 5FU and D-L-Folinic Acid vs. Gemcitabine. Leeds, UK: National Cancer Research Network Trials Portfolio 2004.
65. Neuhaus P, Oettle H, Post S et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proceedings of the American Society of Clinical Oncology 2005; A-4013.
66. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81 (6): 882-5.
67. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7 (6): 593-600.
68. Correale P, Cerretani D, Clerici M et al. Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies. J Chemother 2004; 16 (2):206-10.
69. Colucci G, Giuliani F, Gebbia et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94 (4): 902-10.
70. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002; 29 (6 Suppl 20): 9-16.
71. Schneider BP, Ganjoo KN, Seitz DE et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study. Oncology 2003; 65 (3): 218-23.
72. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22 (18): 3776-83.
73. Louvet C, Labianca R, Hammel P et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. J Clin Oncol 2005; 23 (15): 3509-3516.
74. Moore MJ. Advances in the Understanding and Treatment of Gastrointestinal Cancers Proceedings of the American Society of Clinical Oncology 2005; Gastrointestinal Symposium.
75. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001; 19 (15): 3447-55.
76. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87 (2):161-7.
77. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21 (17): 3296-302.
78. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J Clin Oncol 2004; 22 (13): 2610-6.
79. Schwarz RE, Konduri S, Cafasso D et al. Antianglogenic Combination Treatment Of Experimental Pancreatic Cancer. Proceedings of the American Society of Clinical Oncology 2005; A-153.
80. Burris HA 3rd. Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 2005; 32 (4 Suppl 6): 1-3.